pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG
BRIGHT MINDS BIOSCIENCES
BRIGHT MINDS BIOSCIENCES INC.
Bright Minds Biosciences is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker DRUG. Primary therapeutic focus areas include Cocaine-Related Disorders, Cocaine Dependence, Nicotine Depen
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
- Status
- Public
- HQ
- 19 Vestry St, New York, NY 10013, US
- Employees
- 12
- Programs
- 1063
- Drugs
- 444
- Patents
- 57
ATI-1013 (0.2 g)
Phase 1 · mab · Thromboangiitis Obliterans (Buerger's Disease)
ATI-1013 (0.2 g) for Thromboangiitis Obliterans (Buerger's Disease) is a Phase 1 program (mab) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).
Internal code ATI-1013-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BRIGHT MINDS BIOSCIENCES INC.
- Phase
- Phase 1
- Modality
- mab
- Indication
- Thromboangiitis Obliterans (Buerger's Disease)
- Status
- active
- Trials
- 1